Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Dogwood Therapeutics, Inc (DWTX : NSDQ)

• Company Description    Dogwood Therapeutics Inc. is a biopharmaceutical company. It engages in developing a new class of non-opioid analgesics. The company focuses on the development of Halneuron, IMC-1 and IMC-2. Dogwood Therapeutics Inc., formerly known as Virios Therapeutics Inc., is based in Alpharetta, GA. Number of Employees: 12

• Price / Volume Information    Yesterday's Closing Price: $4.89 Daily Weekly Monthly 20 Day Moving Average: 13,143 shares Shares Outstanding: 1.91 (millions) Market Capitalization: $9.35 (millions) Beta: 1.79 52 Week High: $21.78 52 Week Low: $1.62 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.61% -2.36% 12 Week 1.88% -7.46% Year To Date 96.39% 75.59%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 44 MILTON AVENUE - ALPHARETTA,GA 30009 USA ph: 866-620-8655 fax: - ir@dwtx.com http://www.dwtx.com

• General Corporate Information    Officers Greg Duncan - Chairman and Chief Executive Officer Angela Walsh - Chief Financial Officer; Corporate Secretary and T Ralph Grosswald - Senior Vice President Alan Yu - Director Abel De La Rosa - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92829J203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 1.91 Most Recent Split Date: 10.00 (0.04:1) Beta: 1.79 Market Capitalization: $9.35 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.43 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -59.20% vs. Previous Quarter: 52.73% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - -27.41 03/31/25 - -34.74 12/31/24 - -47.75 Current Ratio 06/30/25 - 7.80 03/31/25 - 7.43 12/31/24 - 5.21 Quick Ratio 06/30/25 - 7.80 03/31/25 - 7.43 12/31/24 - 5.21 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - -9.48 03/31/25 - -9.37 12/31/24 - -7.56 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 19.31

Powered by Zacks Investment Research ©